JAN Stock Forecast & Price Target

Janus Living is supported by a powerful combination of aggressive, accretive capital deployment and strong operating fundamentals in senior housing. Management has already completed about $1.1 billion of acquisitions since the IPO, expects another $500 million before year-end, and is buying at low-6.0% cap rates that should step to 7.5% or better by year 3, supporting roughly 10% 2-year SS NOI CAGR and strong FFO growth estimates of $0.98 in 2026, $1.20 in 2027, and $1.43 in 2028. Its pure-play, RIDEA-structured portfolio, ~$1.0 billion cash balance, and active pipeline of ~$1B of deals under PSA or LOI create substantial runway for earnings accretion, while low-/mid-teens life plan community NOI growth and mid-/high-teens SHOP growth reinforce the positive outlook.

Janus Living is viewed negatively because its valuation already appears stretched at 21x 2027E AFFO and 43% above NAV, while its 5.2% implied cap rate sits well below the healthcare sector and REIT averages. The bearish case assumes seniors housing fundamentals plateau, life plan sales weaken, the recently transitioned portfolio only delivers average growth, and management becomes more cautious on capital deployment, which could trim 4Q27-3Q28 AFFO by about 10%. Additional downside risks include higher supply, a softer U.S. economy, regulatory and reimbursement pressure, operator bankruptcy risk, and uncertainty around CCRCs.